封面
市场调查报告书
商品编码
1775384

全球眼科药品市场:2025-2030 年预测

Global Ophthalmic Drugs Market - Forecasts from 2025 to 2030

出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 142 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

眼科药物市场预计将从 2025 年的 334.95 亿美元成长到 2030 年的 470.31 亿美元,复合年增长率为 7.02%。

眼科药物市场研究为寻求有关市场动态、技术进步、竞争策略等可行见解的行业专业人士提供了不断发展的眼科药物行业的全面分析。该研究检视了适应症、产品类型、剂型、药物类别、给药方式、分销管道和地区等关键细分市场,以提供有关成长机会和挑战的详细见解。

调查概述

我们的眼科药物市场研究旨在提供对市场格局的详细了解。研究涵盖市场驱动因素、限制因素、机会以及影响市场的技术趋势等关键面向。此外,研究还包含一项强而有力的竞争分析,重点主要企业的策略发展,为相关人员提供驾驭这个充满活力的市场所需的洞见。分析涵盖北美、南美、欧洲、中东和非洲以及亚太等地区,确保了全球观点。

竞争格局与分析

眼科用药市场研究深入分析了主要企业及其策略性倡议,并专注于竞争格局。主要企业之间的关键发展突显了市场的动态。

  • 诺华公司:诺华正透过开发视网膜疾病治疗药物,尤其是其抗VEGF疗法Beovu(brolucizumab)来巩固其市场地位。该公司专注于扩大临床试验,以解决湿性老龄化黄斑部病变(AMD)领域尚未满足的需求,并确立了其在该领域的领先地位。
  • 爱尔康公司(Ivantis):爱尔康凭藉微创青光眼手术 (MIGS) 器械 Hydrus Microstent,在青光眼治疗领域取得了重大进展。这项进展体现了爱尔康致力于整合药物-器械联合治疗,并满足对结膜下给药等创新给药方式日益增长的需求。收购 Ivantis 也增强了爱尔康的产品组合,使其在青光眼适应症领域占据竞争优势。

这些发展凸显了领先公司如何利用技术创新和策略联盟来获得市场占有率并满足眼科药品市场不断变化的患者需求。

本报告的主要优点

  • 深刻分析:获得涵盖主要和新兴地区的深入市场洞察,重点关注客户群、政府政策和社会经济因素、消费者偏好、垂直行业和其他细分市场。
  • 竞争格局:了解主要企业采用的策略策略,并了解正确策略的市场渗透潜力。
  • 市场趋势和驱动因素:探索动态因素和关键市场趋势以及它们将如何影响未来的市场发展。
  • 可行的建议:利用洞察力进行策略决策,在动态环境中开闢新的业务流和收益。
  • 适合广泛的使用者:对于新兴企业、研究机构、顾问、中小企业和大型企业来说都是有益且具有成本效益的。

它有什么用途?

产业与市场考量、商业机会评估、产品需求预测、打入市场策略、地理扩张、资本支出决策、法律规范与影响、新产品开发、竞争影响

调查范围

  • 2022 年至 2024 年的实际数据和 2025 年至 2030 年的预测数据
  • 成长机会、挑战、供应链前景、法律规范与趋势分析
  • 竞争定位、策略和市场占有率分析
  • 收益成长和预测细分市场和区域分析(包括国家)
  • 公司概况(尤其是财务状况和关键发展)

目录

第一章执行摘要

第二章市场概述

  • 市场概览
  • 市场定义
  • 调查范围
  • 市场区隔

第三章 经营状况

  • 市场驱动因素
  • 市场限制
  • 市场机会
  • 波特五力分析
  • 产业价值链分析
  • 政策法规
  • 策略建议

第四章 技术展望

5. 全球眼科药物市场(按适应症)

  • 介绍
  • 眼睛干涩
  • 青光眼
  • 感染疾病/发炎/过敏
  • 视网膜问题
  • 其他的

6. 全球眼科药品市场(依产品类型)

  • 介绍
  • 非处方药
  • 处方药

7. 全球眼科药物市场(按剂型)

  • 介绍
  • 液体
  • 半固体
  • 固体的

8. 全球眼科药物市场(依药物类别)

  • 介绍
  • 消炎(药)
  • 麻醉剂
  • 抗过敏
  • 其他的

9. 全球眼科药品市场依交付类型划分

  • 介绍
  • 局部的
    • 玻璃体内
    • 结膜下
  • 系统性
    • 口服
    • 静脉

第 10 章全球眼科药品市场(依通路)

  • 介绍
  • 医院药房
  • 零售药局
  • 网路药局

第 11 章全球眼科药物市场(按地区)

  • 介绍
  • 北美洲
    • 按指示
    • 依产品类型
    • 按药物形式
    • 按药品类别
    • 透过交付
    • 按分销管道
    • 按国家
      • 美国
      • 加拿大
      • 墨西哥
  • 南美洲
    • 按指示
    • 依产品类型
    • 按药物形式
    • 按药品类别
    • 透过交付
    • 按分销管道
    • 按国家
      • 巴西
      • 阿根廷
      • 其他的
  • 欧洲
    • 按指示
    • 依产品类型
    • 按药物形式
    • 按药品类别
    • 透过交付
    • 按分销管道
    • 按国家
      • 英国
      • 德国
      • 法国
      • 西班牙
      • 其他的
  • 中东和非洲
    • 按指示
    • 依产品类型
    • 按药物形式
    • 按药品类别
    • 透过交付
    • 按分销管道
    • 按国家
      • 沙乌地阿拉伯
      • 阿拉伯聯合大公国
      • 其他的
  • 亚太地区
    • 按指示
    • 依产品类型
    • 按药物形式
    • 按药品类别
    • 透过交付
    • 按分销管道
    • 按国家
      • 中国
      • 日本
      • 印度
      • 韩国
      • 台湾
      • 其他的

第十二章竞争格局及分析

  • 主要企业和策略分析
  • 市场占有率分析
  • 合併、收购、协议和合作
  • 竞争对手仪表板

第十三章 公司简介

  • Sun Pharmaceutical Industries, Inc.
  • AbbVie
  • Alcon Inc.(Ivantis)
  • Mundipharma International
  • F. Hoffmann-La Roche Ltd
  • Novartis AG
  • Sentiss Pharma Pvt. Ltd.
  • Santen Pharmaceutical Co., Ltd
  • Bausch & Lomb
  • Bayer AG
  • Aerie Pharmaceuticals, Inc

第十四章 附录

  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关人员的主要利益
  • 调查方法
  • 简称
简介目录
Product Code: KSI061613483

The Global Ophthalmic Drugs Market is expected to grow from USD 33.495 billion in 2025 to USD 47.031 billion in 2030, at a CAGR of 7.02%.

The Global Ophthalmic Drugs Market Study provides a comprehensive analysis of the evolving ophthalmic drugs industry, tailored for industry experts seeking actionable insights into market dynamics, technological advancements, and competitive strategies. This study examines key market segments, including indications, product types, drug forms, drug classes, delivery methods, distribution channels, and geographical regions, offering a detailed perspective on growth opportunities and challenges.

Study Overview

The Global Ophthalmic Drugs Market Study is structured to deliver a granular understanding of the market landscape. It covers critical aspects such as market drivers, restraints, opportunities, and technological trends shaping the industry. The study also includes a robust competitive analysis, highlighting strategic developments from key players to equip stakeholders with the insights needed to navigate this dynamic market. The analysis spans regions, including North America, South America, Europe, Middle East and Africa, and Asia Pacific, ensuring a global perspective.

Competitive Environment and Analysis

In the Global Ophthalmic Drugs Market Study, the competitive environment is a focal point, offering an in-depth look at major players and their strategic initiatives. Key developments from leading companies underscore the dynamic nature of the market:

  • Novartis AG: Novartis has strengthened its position through advancements in retinal disorder treatments, notably with its anti-VEGF therapy, Beovu (brolucizumab). The company has focused on expanding clinical trials to address unmet needs in wet age-related macular degeneration (AMD), positioning itself as a leader in the retinal problems segment. Its strategic partnerships with research institutions aim to accelerate innovation in intraocular delivery methods, enhancing treatment efficacy.
  • Alcon Inc. (Ivantis): Alcon has made significant strides in glaucoma management with its Hydrus Microstent, a minimally invasive glaucoma surgery (MIGS) device. This development reflects Alcon's commitment to integrating drug-device combination therapies, addressing the growing demand for innovative delivery methods like subconjunctival administration. The company's acquisition of Ivantis has bolstered its portfolio, enhancing its competitive edge in the glaucoma indication segment.

These developments highlight how key players are leveraging innovation and strategic collaborations to capture market share and address evolving patient needs in the Global Ophthalmic Drugs Market Study.

Key Benefits of this Report:

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data from 2022 to 2024 & forecast data from 2025 to 2030
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.

Segmentation:

By Indication

  • Dry Eye
  • Glaucoma
  • Infection/Inflammation/Allergies
  • Retinal Problems
  • Others

By Product type

  • OTC Drug
  • Prescription Drug

By Drug Form

  • Liquid
  • Semi-solid
  • Solid

By Drug Class

  • Anti-Inflammatory
  • Anesthetic
  • Anti-Allergy
  • Others

By Delivery Method

  • Topical (Eye Drops, Ointments)
  • Intraocular
  • Intravitreal
  • Subconjunctival
  • Systemic
  • Oral
  • Intravenous

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Geography

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • UK
  • Germany
  • France
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Others
  • Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Indonesia
  • Taiwan
  • Thailand
  • Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

  • 2.1. Market Overview
  • 2.2. Market Definition
  • 2.3. Scope of the Study
  • 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Porter's Five Forces Analysis
  • 3.5. Industry Value Chain Analysis
  • 3.6. Policies and Regulations
  • 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. GLOBAL OPHTHALMIC DRUGS MARKET BY INDICATION

  • 5.1. Introduction
  • 5.2. Dry Eye
  • 5.3. Glaucoma
  • 5.4. Infection/Inflammation/Allergies
  • 5.5. Retinal Problems
  • 5.6. Others

6. GLOBAL OPHTHALMIC DRUGS MARKET BY PRODUCT TYPE

  • 6.1. Introduction
  • 6.2. OTC Drug
  • 6.3. Prescription Drug

7. GLOBAL OPHTHALMIC DRUGS MARKET BY DRUG FORM

  • 7.1. Introduction
  • 7.2. Liquid
  • 7.3. Semi-solid
  • 7.4. Solid

8. GLOBAL OPHTHALMIC DRUGS MARKET BY DRUG CLASS

  • 8.1. Introduction
  • 8.2. Anti-Inflammatory
  • 8.3. Anesthetic
  • 8.4. Anti-Allergy
  • 8.5. Others

9. GLOBAL OPHTHALMIC DRUGS MARKET BY DELIVERY METHOD

  • 9.1. Introduction
  • 9.2. Topical
  • 9.3. Intraocular
    • 9.3.1. Intravitreal
    • 9.3.2. Subconjunctival
  • 9.4. Systemic
    • 9.4.1. Oral
    • 9.4.2. Intravenous

10. GLOBAL OPHTHALMIC DRUGS MARKET BY DISTRIBUTION CHANNEL

  • 10.1. Introduction
  • 10.2. Hospital Pharmacies
  • 10.3. Retail Pharmacies
  • 10.4. Online Pharmacies

11. GLOBAL OPHTHALMIC DRUGS MARKET BY GEOGRAPHY

  • 11.1. Introduction
  • 11.2. North America
    • 11.2.1. By Indication
    • 11.2.2. By Product Type
    • 11.2.3. By Drug Form
    • 11.2.4. By Drug Class
    • 11.2.5. By Delivery Method
    • 11.2.6. By Distribution Channel
    • 11.2.7. By Country
      • 11.2.7.1. USA
      • 11.2.7.2. CanadaHybrid in
      • 11.2.7.3. Mexico
  • 11.3. South America
    • 11.3.1. By Indication
    • 11.3.2. By Product Type
    • 11.3.3. By Drug Form
    • 11.3.4. By Drug Class
    • 11.3.5. By Delivery Method
    • 11.3.6. By Distribution Channel
    • 11.3.7. By Country
      • 11.3.7.1. Brazil
      • 11.3.7.2. Argentina
      • 11.3.7.3. Others
  • 11.4. Europe
    • 11.4.1. By Indication
    • 11.4.2. By Product Type
    • 11.4.3. By Drug Form
    • 11.4.4. By Drug Class
    • 11.4.5. By Delivery Method
    • 11.4.6. By Distribution Channel
    • 11.4.7. By Country
      • 11.4.7.1. United Kingdom
      • 11.4.7.2. Germany
      • 11.4.7.3. France
      • 11.4.7.4. Spain
      • 11.4.7.5. Others
  • 11.5. Middle East and Africa
    • 11.5.1. By Indication
    • 11.5.2. By Product Type
    • 11.5.3. By Drug Form
    • 11.5.4. By Drug Class
    • 11.5.5. By Delivery Method
    • 11.5.6. By Distribution Channel
    • 11.5.7. By Country
      • 11.5.7.1. Saudi Arabia
      • 11.5.7.2. UAE
      • 11.5.7.3. Others
  • 11.6. Asia Pacific
    • 11.6.1. By Indication
    • 11.6.2. By Product Type
    • 11.6.3. By Drug Form
    • 11.6.4. By Drug Class
    • 11.6.5. By Delivery Method
    • 11.6.6. By Distribution Channel
    • 11.6.7. By Country
      • 11.6.7.1. China
      • 11.6.7.2. Japan
      • 11.6.7.3. India
      • 11.6.7.4. South Korea
      • 11.6.7.5. Taiwan
      • 11.6.7.6. Others

12. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 12.1. Major Players and Strategy Analysis
  • 12.2. Market Share Analysis
  • 12.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 12.4. Competitive Dashboard

13. COMPANY PROFILES

  • 13.1. Sun Pharmaceutical Industries, Inc.
  • 13.2. AbbVie
  • 13.3. Alcon Inc. (Ivantis)
  • 13.4. Mundipharma International
  • 13.5. F. Hoffmann-La Roche Ltd
  • 13.6. Novartis AG
  • 13.7. Sentiss Pharma Pvt. Ltd.
  • 13.8. Santen Pharmaceutical Co., Ltd
  • 13.9. Bausch & Lomb
  • 13.10. Bayer AG
  • 13.11. Aerie Pharmaceuticals, Inc

14. APPENDIX

  • 14.1. Currency
  • 14.2. Assumptions
  • 14.3. Base and Forecast Years Timeline
  • 14.4. Key benefits for the stakeholders
  • 14.5. Research Methodology
  • 14.6. Abbreviations